Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Treacy

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
International Immunopharmacology|February 26, 2026
Cyclophosphamide-pomalidomide combination alters the tumour cell secretome and enhances the anti-myeloma activity of elotuzumab through NK cell-mediated cytotoxicityClaire L Feerick, Lei Lei, Dawn Swan, et al.
Plos One|August 11, 2012
Adenoviral transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantationOliver Treacy, Aideen E Ryan, Teresa Heinzl, et al.
Stem Cell Research & Therapy|April 7, 2021
Subconjunctival administration of low-dose murine allogeneic mesenchymal stromal cells promotes corneal allograft survival in miceOliver Treacy, Kevin Lynch, Nick Murphy, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 5, 2013
Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantationAideen E Ryan, Paul Lohan, Lisa O'Flynn, et al.
Cancer Immunology Research|September 20, 2018
Stromal Cell PD-L1 Inhibits CD8<sup>+</sup> T-cell Antitumor Immune Responses and Promotes Colon CancerGrace O'Malley, Oliver Treacy, Kevin Lynch, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 13, 2020
TGF-β1-Licensed Murine MSCs Show Superior Therapeutic Efficacy in Modulating Corneal Allograft Immune Rejection In VivoKevin Lynch, Oliver Treacy, Xizhe Chen, et al.
Oncoimmunology|February 8, 2021
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosisSerika D Naicker, Claire L Feerick, Kevin Lynch, et al.
Iscience|September 23, 2024
Tumor-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signalingNiamh A Leonard, Shania M Corry, Eileen Reidy, et al.
Journal for Immunotherapy of Cancer|October 19, 2025
Stromal cells modulate innate immune cell phenotype and function in colorectal cancer via the Sialic acid/Siglec axisAoise O'Neill, Norashikin Zakaria, Courtney Bull, et al.
Cell Reports|May 11, 2023
Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironmentHannah Egan, Oliver Treacy, Kevin Lynch, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
International Immunopharmacology|February 26, 2026
Cyclophosphamide-pomalidomide combination alters the tumour cell secretome and enhances the anti-myeloma activity of elotuzumab through NK cell-mediated cytotoxicityClaire L Feerick, Lei Lei, Dawn Swan, et al.
Plos One|August 11, 2012
Adenoviral transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantationOliver Treacy, Aideen E Ryan, Teresa Heinzl, et al.
Stem Cell Research & Therapy|April 7, 2021
Subconjunctival administration of low-dose murine allogeneic mesenchymal stromal cells promotes corneal allograft survival in miceOliver Treacy, Kevin Lynch, Nick Murphy, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 5, 2013
Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantationAideen E Ryan, Paul Lohan, Lisa O'Flynn, et al.
Cancer Immunology Research|September 20, 2018
Stromal Cell PD-L1 Inhibits CD8<sup>+</sup> T-cell Antitumor Immune Responses and Promotes Colon CancerGrace O'Malley, Oliver Treacy, Kevin Lynch, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 13, 2020
TGF-β1-Licensed Murine MSCs Show Superior Therapeutic Efficacy in Modulating Corneal Allograft Immune Rejection In VivoKevin Lynch, Oliver Treacy, Xizhe Chen, et al.
Oncoimmunology|February 8, 2021
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosisSerika D Naicker, Claire L Feerick, Kevin Lynch, et al.
Iscience|September 23, 2024
Tumor-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signalingNiamh A Leonard, Shania M Corry, Eileen Reidy, et al.
Journal for Immunotherapy of Cancer|October 19, 2025
Stromal cells modulate innate immune cell phenotype and function in colorectal cancer via the Sialic acid/Siglec axisAoise O'Neill, Norashikin Zakaria, Courtney Bull, et al.
Cell Reports|May 11, 2023
Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironmentHannah Egan, Oliver Treacy, Kevin Lynch, et al.
Pageof 3